Last reviewed · How we verify
low-dose ticagrelor
Low-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.
Low-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events. Used for Acute coronary syndrome, Secondary prevention of thrombotic cardiovascular events.
At a glance
| Generic name | low-dose ticagrelor |
|---|---|
| Also known as | low-dose ticagrelor(22.5 mg twice daily) |
| Sponsor | First Affiliated Hospital of Harbin Medical University |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that blocks ADP-induced platelet activation more rapidly and potently than other P2Y12 inhibitors. At lower doses, it maintains antiplatelet efficacy while potentially reducing bleeding risk compared to standard dosing. The drug is used to prevent thrombotic cardiovascular events in acute coronary syndromes and other high-risk populations.
Approved indications
- Acute coronary syndrome
- Secondary prevention of thrombotic cardiovascular events
Common side effects
- Bleeding
- Bradycardia
- Dyspnea
- Ventricular pauses
Key clinical trials
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study (PHASE4)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- One-Month DAPT in CABG Patients (PHASE3)
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis (PHASE3)
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (PHASE4)
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low-dose ticagrelor CI brief — competitive landscape report
- low-dose ticagrelor updates RSS · CI watch RSS
- First Affiliated Hospital of Harbin Medical University portfolio CI